• 1
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
  • 2
    Sawaya R, Bindal RK, Lang FF, Abi-Said D. Metastatic brain tumors. In: Kaye AH, Laws ERJr, eds. Brain Tumors. 2nd ed. Philadelphia: Churchill Livingstone; 2001: 999-1026.
  • 3
    Lotze MT, Dallal RM, Kirkwood JM, Flickinger JC. Cutaneous melanoma. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Vol 2. Philadelphia: Lippincott Williams and Wilkins; 2001: 2012-2069.
  • 4
    Fife KM, Colman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004; 22: 1293-1300.
  • 5
    Raizer JJ, Hwu WJ, Panageas KS, et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol. 2008; 10: 199-207.
  • 6
    Sampson JH, Carter JHJr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998; 88: 11-20.
  • 7
    Skibber JM, Soong SJ, Austin L, Balch CM, Sawaya RE. Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol. 1996; 3: 118-123.
  • 8
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 9
    Buzaid A, Legha SS, Balch CM, et al. Pilot study of preoperative chemotherapy with cisplatin, vinblastine, and dacarbazine in patients with local-regional recurrence of melanoma. Cancer. 1994; 74: 2476-2482.
  • 10
    Buzaid AC, Colome M, Bedikian A, et al. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res. 1998; 8: 549-556.
  • 11
    Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002; 20: 2045-2052.
  • 12
    Kim KB, Legha SS, Gonzalez R, et al. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009; 19: 4249.
  • 13
    Kim KB, Eton O, East MJ, et al. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma. Cancer. 2004; 101: 596-603.
  • 14
    Legha S, Plager C, Ring S, et al. A phase-II study of biochemotherapy using interleukin-2 (IL-2) + interferon alpha-2A (IFN) in combination with cisplatin (C), vinblastine (V) and DTIC (D) in patients with metastatic melanoma. Presented at: 28th Annual Meeting of the American Society of Clinical Oncology, May 17-19, 1992, San Diego, CA. 1992;11: 343.
  • 15
    Legha SS, Ring S, Bedikian A, et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol. 1996; 7: 827-835.
  • 16
    Legha SS, Ring S, Eton O, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol. 1998; 16: 1752-1759.
  • 17
    Legha SS, Ring S, Papadopoulos N, Plager C, Chawla S, Benjamin R. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer. 1989; 64: 2024-2029.
  • 18
    Papadopoulos NE, Bedikian AY, Ring S, Kim KB, Camacho L, Eton O. Phase II study of CTD (cisplatin, paclitaxel, DTIC) in metastatic melanoma (MM). Presented at: 39th American Society of Clinical Oncology Annual Meeting, May 31-June 3, 2003, Chicago, IL. 2003;22: 2889.
  • 19
    Papadopoulos NE, Eton O, Kim KB, Camacho LH, Hwu P, Bedikian AY. Phase II study of “hybrid” biochemotherapy for advanced melanoma. Presented at: 42nd American Society of Clinical Oncology Annual Meeting, June 2-6, 2006, Atlanta, GA. 2006;24: 18007.
  • 20
    Sanguino AM, Bedikian AY, Legha SS, et al. Long-term clinical results of the combination of cisplatin (C), vinblastine (V), DTIC (D) and interferon-alfa (I) with or without tamoxifen (T) for metastatic melanoma. Presented at: 42nd American Society of Clinical Oncology Annual Meeting. 2006;24: 8039.
  • 21
    Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist. 2007; 12: 884-898.
  • 22
    Biasco G, Pantaleo MA, Casadei S. Treatment of brain metastases of malignant melanoma with temozolomide. N Engl J Med. 2001; 345: 621-622.
  • 23
    Danson SJ, Middleton MR. Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther. 2001; 1: 13-19.
  • 24
    Dvorak J, Melichar B, Zizka J, Hadzi-Nikolov D, Petera J. Complete response of multiple melanoma brain metastases after treatment with temozolomide. Onkologie. 2004; 27: 171-174.
  • 25
    Taillibert S, Laigle-Donadey F, Chodkiewicz C, Sanson M, Hoang-Xuan K, Delattre JY. Leptomeningeal metastases from solid malignancy: a review. J Neurooncol. 2005; 75: 85-99.
  • 26
    Schneider F, Putzier M. Primary leptomeningeal melanoma. Spine (Phila Pa 1976). 2002; 27: E545-E547.
  • 27
    Rosenthal G, Gomori JM, Tobias S, Diment J, Shoshan Y. Unusual cases involving the CNS and nasal sinuses: Case 1. Primary leptomeningeal melanoma. J Clin Oncol. 2003; 21: 3875-3877.
  • 28
    Morris SL, Low SH, A'Hern RP, et al. A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma. Br J Cancer. 2004; 91: 829-833.
  • 29
    Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol. 2004; 22: 2101-2107.
  • 30
    Atkins MB, Sosman JA, Agarwala S, et al. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer. 2008; 113: 2139-2145.
  • 31
    Krown SE, Niedzwiecki D, Hwu W-J, et al. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer. 2006; 107: 1883-1890.
  • 32
    Margolin K, Atkins B, Thompson A, et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol. 2002; 128: 214-218.
  • 33
    Mornex F, Thomas L, Mohr P, et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res. 2003; 13: 97-103.
  • 34
    Davies MA, Samuels Y. Analysis of the genome to personalize therapy for melanoma [published online ahead of print August 9, 2010]. Oncogene doi:10.1038.onc.2010.323.